Condition: Combined Hepatocellular-cholangiocarcinoma · Combined Hepatocellular Carcinoma and Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma · Sponsor: Zhongda Hospital
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial intelligence and multi-omics, and exploring the optimal treatment strategies for patients with different subtypes, helping clinicians to screen the most beneficial groups of various treatment schemes, and providing new ideas for safe treatment of high-risk patients.
This description comes directly from the study's public registry record.
Gao-Jun Teng, M.D · +86-02583272121 · gjteng@vip.sina.com
Always discuss trial participation with your own doctor first.
| Zhongda Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06849180